Fruquintinib
Brand names: Fruzaqla · Active ingredient: Fruquintinib
In short: FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.
What is Fruquintinib used for?
FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.
Fruquintinib dosage
The recommended dose of FRUZAQLA is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take FRUZAQLA with or without food at approximately the same time each day.
Swallow the FRUZAQLA capsule whole.
Take a missed dose if less than 12 hours have passed since the missed scheduled dose. Do not take two doses on the same day to make up for a missed dose.
Do not take an additional dose if vomiting occurs after taking FRUZAQLA but continue with the next scheduled dose.
The recommended dose reductions for adverse reactions are provided in Table 1.
Dose Level | FRUZAQLA Dosage
First dose reduction | 4 mg orally once daily
Second dose reduction | 3 mg orally once daily
Permanently discontinue FRUZAQLA in patients unable to tolerate 3 mg orally once daily.
The recommended dosage modifications for adverse reactions are provided in Table 2.
Adverse Reaction | SeveritySeverity as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. | FRUZAQLA Dosage Modification
Hypertension
| Grade 3 | Withhold FRUZAQLA for Grade 3 hypertension that persists despite optimal anti-hypertensive therapy.
If hypertension fully resolves or recovers to Grade 1, resume at the next lower dose level.
Grade 4 | Permanently discontinue FRUZAQLA.
Hemorrhagic Events
| Grade 2 | Withhold FRUZAQLA until bleeding fully resolves or recovers to Grade 1.
Resume at the next lower dose level.
Grade 3 or Grade 4 | Permanently discontinue FRUZAQLA.
Hepatotoxicity
| Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times upper limit of normal (ULN), or greater than 3 times baseline if baseline was abnormal;
or
bilirubin greater than 1.5 times ULN, or greater than 1.5 times baseline if baseline was abnormal | Withhold FRUZAQLA and monitor AST, ALT and total bilirubin until resolution to Grade 1 or baseline.
Resume at the next lower dose level.
ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 2 times ULN (in the absence of cholestasis or hemolysis) | Permanently discontinue FRUZAQLA.
AST or ALT greater than 20 times ULN if baseline was normal, or greater than 20 times baseline if baseline was abnormal;
or
bilirubin greater than 10 times ULN if baseline was normal, or greater than 10 times baseline if baseline was abnormal | Permanently discontinue FRUZAQLA.
Proteinuria
| 2 grams or greater proteinuria in 24 hours | Withhold FRUZAQLA until proteinuria fully resolves or is <1 gram/24 hours.
Upon recovery, resume at the next lower dose level.
Permanently discontinue FRUZAQLA for nephrotic syndrome or if proteinuria does not recover to <1 gram/24 hours. …
How to take Fruquintinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Hypertension
Advise patients to undergo regular blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if symptoms from hypertension occur including severe headache, lightheadedness, or new neurologic symptoms .
Hemorrhages
Advise patients that FRUZAQLA may increase the risk of bleeding and to contact their healthcare provider for unusual, severe, or persistent bleeding, bruising, or symptoms of bleeding, such as lightheadedness .
Infections
Advise patients to contact their healthcare provider if they experience signs and symptoms of infection .
Gastrointestinal Perforation
Advise patients to contact a healthcare provider immediately if they experience severe abdominal pains, or other symptoms of gastrointestinal perforation or fistula .
Hepatotoxicity
Advise patients that they will need to undergo laboratory tests to monitor liver function and to report any new symptoms indicating hepatic toxicity or failure . …
Warnings & precautions
Do not take this medicine if: None.
FRUZAQLA can cause hypertension. Hypertension occurred in 450 of 911 (49%) patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). The median time to first onset of hypertension was 14 days from first dose of FRUZAQLA.
Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly the first month, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on the severity of hypertension .
FRUZAQLA can cause serious hemorrhagic events, which may be fatal. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced a gastrointestinal hemorrhage, including 13 patients (1%) with a Grade ≥3 event and 2 patients with fatal hemorrhages.
Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants .
FRUZAQLA can cause an increased risk of infections, including fatal infections. In 781 patients treated with FRUZAQLA across three randomized, placebo-controlled trials, the overall incidence of infections was higher (18% vs. 12%) including for fatal infections (1% vs. 0.3%) as compared to the placebo arms (n=391).
In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%).
Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. …
Fruquintinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypertension .
Hemorrhagic Events .
Infections .
Gastrointestinal Perforation .
Hepatotoxicity .
Proteinuria .
Palmar-Plantar Erythrodysesthesia (PPE) .
Posterior Reversible Encephalopathy Syndrome (PRES) .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS and below reflects exposure to FRUZAQLA as a single agent in 911 patients with mCRC who were enrolled in three randomized, placebo-controlled studies (FRESCO-2, FRESCO and 2012-013-00CH1) (N=781); three open-label studies (2009-013-00CH1, 2012-013-00CH3 and 2015-013-00US1) (N=124); and an open-label lead-in cohort of FRESCO-2 (N=6). Among the 911 patients who received FRUZAQLA, 23% were exposed for 6 months or longer and 3.5% were exposed for greater than one year. These patients received at least one dose of FRUZAQLA at the recommended dosage of 5 mg daily for the first 21 days of each 28-day cycle. The median age was 60 years (range: 23 to 82) and 34% were 65 years of age or older. …
Drug interactions
Strong CYP3A Inducers
Avoid concomitant use of drugs that are strong CYP3A inducers with FRUZAQLA.
Concomitant use with a strong CYP3A inducer may decrease fruquintinib Cmax and AUC , which may reduce the efficacy of FRUZAQLA.
Moderate CYP3A Inducers
If possible, avoid concomitant use of drugs that are moderate CYP3A inducers with FRUZAQLA. If it is not possible to avoid concomitant use of a moderate CYP3A inducer and fruquintinib, continue to administer FRUZAQLA at the recommended dosage.
Concomitant use with a moderate CYP3A inducer may decrease fruquintinib Cmax and AUC , which may reduce the efficacy of FRUZAQLA.
About this medicine
Fruquintinib is a kinase inhibitor with the chemical name 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide. Its molecular formula is C21H19N3O5, which corresponds to a molecular weight of 393.39 g/mol. Fruquintinib has the following chemical structure:
Fruquintinib is a white to off-white powder with a dissociation constant (pKa) of 2.78. The aqueous solubility of fruquintinib is pH-dependent with a solubility of 0.9 μg/mL at pH 6.8 that increases under acidic conditions to 129.9 μg/mL at pH 1.
FRUZAQLA (fruquintinib) capsules for oral administration contain 1 mg or 5 mg of fruquintinib. The inactive ingredients are corn starch, microcrystalline cellulose, and talc. The 1 mg capsule shell contains FD&C Yellow No. 5 (tartrazine), FD&C Yellow No. 6 (sunset yellow FCF), gelatin, and titanium dioxide. The 5 mg capsule shell contains FD&C Blue No. 1 (brilliant blue FCF), FD&C Red No. 40 (allura red AC), gelatin, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 186d786e-dc8a-45f2-b5e1-01ac0201879f. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate